Prophylaxis News and Research

RSS

BioInvent, ThromboGenics initiate TB-402 Phase IIb trial for VTE prophylaxis

ThromboGenics NV and co-development partner BioInvent International announce today that the first patient has been dosed in a Phase IIb trial with their novel long-acting anticoagulant TB-402 for the prophylaxis of venous thromboembolism after total hip surgery.

27 Apr 2011

Azithromycin holds promise for preventing BPD in Ureaplasma-infected preterm infants

A study performed by University of Kentucky researchers shows promise for the use of azithromycin in treating Ureaplasma-colonized or infected premature infants to prevent bronchopulmonary dysplasia (BPD).

27 Apr 2011

FDA approves Bayer's new Kogenate FS storage option for hemophilia A treatment

Bayer HealthCare Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved a new storage option for Kogenate FS, antihemophilic factor, now allowing the product to be stored at room temperature for up to one year.

26 Apr 2011

Infants with bronchopulmonary dysplasia can benefit from azithromycin therapy

A study performed by University of Kentucky researchers shows promise for the use of azithromycin in treating Ureaplasma-colonized or infected premature infants to prevent bronchopulmonary dysplasia.

26 Apr 2011

BMY to present belatacept Phase III new data at American Transplant Congress

New data on belatacept, an investigational selective T cell costimulation blocker being studied for use in renal transplantation by Bristol-Myers Squibb Company, will be presented at the American Transplant Congress April 30 - May 4, 2011 in Philadelphia.

26 Apr 2011

Group B streptococci continues to increase risk of sepsis in newborns

Bloodstream infections in newborns can lead to serious complications with substantial morbidity and mortality. What's more, the pathogens responsible for neonatal infections have changed over time. In recent years, however, antibiotic prophylaxis given to at-risk mothers has reduced the incidence of early-onset group B streptococcal infections among their babies.

25 Apr 2011

GM-SCF therapy can reduce flu symptoms and prevent death

New research on mice has shown that pulmonary administration of granulocyte macrophage-colony stimulating factor significantly reduces flu symptoms and prevents death after a lethal dose influenza virus.

22 Apr 2011

Study shows possibility of women living with AIDS to breastfeed with lower risk

In low-income countries, 1.4 million women are living with the Aids virus. If no prevention measures are taken, the risk for future mothers of transmitting HIV to their child in utero, during delivery or when breastfeeding is 35%.

20 Apr 2011

Researchers to wind down HIV prevention trial in women after interim results find drug not offering protection from HIV

Researchers on Monday announced they were calling off a trial to test whether taking an oral HIV drug reduces the risk of HIV infection in women after interim analysis of the study showed women taking the medication were no less likely to become infected with HIV than those who were not taking the medicine, the Associated Press reports.

20 Apr 2011

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

On the heels of Centers for Disease Control announcement earlier today that an ongoing study of the use of Gilead's top selling AIDS treatment, Truvada, as a possible form of pre-exposure prophylaxis for HIV prevention in women is being abruptly halted because the, "…trial could not demonstrate efficacy," the AIDS Healthcare Foundation renewed its call on Gilead Sciences to slow its fast track pursuit of its application for FDA approval of use of its AIDS drug as a possible form of HIV prevention.

20 Apr 2011

African AIDS drug trial stopped prematurely

One of the studies in three African countries where women were given an AIDS drug to prevent HIV infection is being stopped because the project is not working, researchers said Monday. These women on the trial were taking a daily dose of the drug Truvada or a look-alike placebo pill and had an equal chance of becoming infected. The ones taking Truvada were expected to have had a much lower infection rate.

19 Apr 2011

Baxter enters definitive agreement to acquire Prism

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire privately-held Prism Pharmaceuticals, Inc., a specialty pharmaceutical company based in King of Prussia, PA. Prism Pharmaceuticals has developed and received U.S. Food and Drug Administration (FDA) approval for multiple presentations of NEXTERONE® (amiodarone HCl), an antiarrhythmic agent.

From Baxter International Inc. 18 Apr 2011

Ortho-McNeil Neurologics announces voluntary recall of TOPAMAX 100mg Tablets

Ortho-McNeil Neurologics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., today announced it is voluntarily recalling two lots of TOPAMAX® (topiramate) 100mg Tablets. These two lots were shipped between 10/19/2010 and 12/28/2010 and distributed in the U.S. and Puerto Rico.

15 Apr 2011

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.

6 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011

Regado's REG1 system Phase 2b trial results presented at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced today the primary results of the RADAR Phase 2b clinical trial of the company's lead product, the anticoagulation system REG1, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans, LA.

4 Apr 2011

Donation after cardiac death may broaden the scope of organ donor selection

Findings from two new studies presented today at the International Liver CongressTM confirm that there are options for clinicians to expand the pool of liver grafts for use in patients with liver disease.

1 Apr 2011

Allscripts ED 7.0 receives Complete EHR certification

Allscripts announced today that Allscripts ED™ 7.0, the company's standalone Emergency Department Information System (EDIS), is 2011/2012 compliant and was certified as a Complete EHR on March 2, 2011 by the Certification Commission for Health Information Technology, an ONC-ATCB, in accordance with the applicable hospital certification criteria adopted by the Secretary of Health and Human Services.

30 Mar 2011

Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University, will present results of the RADAR Phase 2b clinical trial for the Company's lead product, the REG1 anticoagulation system, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo.

29 Mar 2011

ViroPharma presents Cinryze data against HAE at AAAAI Annual Meeting

ViroPharma Incorporated today announced data presented in two poster presentations relating to Cinryze at the 2011 American Academy of Allergy Asthma & Immunology Annual Meeting, March 18 through 22, in San Francisco, CA.

23 Mar 2011